ShigaPlexIM annual meeting 2025
- europevaccine
- Apr 1
- 2 min read
On 19 March 2025, the 5th ShigaPlexIM annual meeting was held at the Centre for Infectious Disease Research in Zambia - CIDRZ, Lusaka Zambia.
March 2025
Consortium partners from Zambia (Centre for Infectious Disease Research in Zambia - CIDRZ), the Netherlands (Leiden University Medical Center (LUMC), Burkina Faso (Groupe de Recherche Action en Santé - GRAS), Germany (European Vaccine Initiative - EVI), Sweden (University of Gothenburg - UGOT) and Switzerland (Foundation for Appropriate Technologies in Health - FATH), joined either in person or virtually to discuss the project achievements and the future strategy.
During this fruitful annual meeting, partners discussed the progress of the phase Ia/b trial at LUMC and its imminent start at CIDRZ, as all ethics and regulatory approvals are now in place. The implementation of the immunoassays developed for the clinical trial was presented. The planning of the publications resulting from the two sero-epidemiology studies on the Shigella burden in children under 5 conducted at CIDRZ and GRAS, as well as the capacity-strengthening activities, were presented.
The ShigaPlexIM project Scientific and Ethics Advisory Committee members Dr Odile Ouwe Missi Oukem and Prof. Ellis Owusu-Dabo joined the meeting in person and virtually, respectively, to support and advise the consortium towards its commitment to develop a new vaccine to protect against Shigella infection.
On 20 March 2025, the consortium partners were invited to the CIDRZ headquarters to attend a presentation by Victor Cnossen, a research physician/PhD student at LUMC and Centre for Human Drug Research (CHDR) of Leyden, in the Netherlands, on controlled human infection studies conducted at CHDR.
Later the same day, the consortium partners and SEAC members were invited to visit the CIDRZ headquarters, clinical laboratory and clinical trial site, where lively discussions were carried out on the upcoming clinical trial.
This project is part of the EDCTP2 Programme supported by the European Union (RIA2018V-2308)
Comments